Novavax, Inc.
NVAX
$6.78
$0.182.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.06B | 1.08B | 1.25B | 682.16M | 885.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.06B | 1.08B | 1.25B | 682.16M | 885.19M |
| Cost of Revenue | 406.63M | 436.45M | 495.64M | 542.87M | 701.75M |
| Gross Profit | 658.02M | 642.26M | 759.33M | 139.29M | 183.44M |
| SG&A Expenses | 220.33M | 255.01M | 315.65M | 350.35M | 432.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 647.83M | 712.33M | 832.15M | 914.09M | 1.18B |
| Operating Income | 416.82M | 366.39M | 422.81M | -231.93M | -290.02M |
| Income Before Tax | 350.68M | 431.39M | 488.52M | -176.62M | -279.74M |
| Income Tax Expenses | 8.94M | 8.56M | 9.82M | 10.88M | 5.12M |
| Earnings from Continuing Operations | 341.75 | 422.82 | 478.70 | -187.50 | -284.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 341.75M | 422.82M | 478.70M | -187.50M | -284.86M |
| EBIT | 416.82M | 366.39M | 422.81M | -231.93M | -290.02M |
| EBITDA | 451.83M | 407.51M | 467.50M | -183.44M | -243.25M |
| EPS Basic | 2.13 | 2.61 | 3.05 | -1.22 | -2.16 |
| Normalized Basic EPS | 1.67 | 1.50 | 1.79 | -0.85 | -1.28 |
| EPS Diluted | 1.79 | 2.28 | 2.66 | -1.33 | -2.26 |
| Normalized Diluted EPS | 1.45 | 1.28 | 1.53 | -0.93 | -1.35 |
| Average Basic Shares Outstanding | 645.66M | 643.36M | 629.72M | 608.59M | 572.02M |
| Average Diluted Shares Outstanding | 677.43M | 675.13M | 663.77M | 626.06M | 589.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |